Back to results
US 9,168,300 B2Granted
MET-binding agents and uses thereof
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. Gurney, Ming-Hong Xie, Christopher John Bond
Life of this patent
Estimating the term…
Abstract
The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
Claims21
A bispecific agent comprising:
- a) a first binding site comprising an antigen-binding site of an antibody that specifically binds human MET, wherein the antigen-binding site comprises a heavy chain CDR1 comprising ASYAWS (SEQ ID NO:1), a heavy chain CDR2 comprising YISYSGGTDYNPSLKS (SEQ ID NO:2), and a heavy chain CDR3 comprising KGAY (SEQ ID NO:3);
- and a light chain CDR1 comprising SASSSVSSSYLY (SEQ ID NO:4), a light chain CDR2 comprising STSNLAS (SEQ ID NO:5), and a light chain CDR3 comprising HQWSSYPYT (SEQ ID NO:6);
- and
- b) a second binding site that specifically binds one or more components of the WNT pathway, wherein the second binding site comprises a soluble human frizzled 8 (FZD8) receptor.
1 more element
An isolated antibody that specifically binds human MET, which comprise:
- a heavy chain CDR1 comprising ASYAWS (SEQ ID NO. 1), a heavy chain CDR2comprising YISYSGGTDYNPSLKS (SEQ ID NO:
- 2) and a heavy chain CDR3 comprising KGAY (SEQ ID NO:
- 3);
- and a light chain CDR1 comprising SASSSVSSSYLY (SEQ ID NO:
- 4), a light chain CDR2 comprising STSNLAS (SEQ ID NO:
- 5), and a light chain CDR 3 comprising HQWSSYPYT (SEQ ID NO:6).
3 more elements
Dependencies are inferred from the claim text.